The UK regulatory authority has cleared the path for some patients with generalised myasthenia gravis (gMG) to get early access to Argenx' efgartigimod while it reviews the marketing application for ...
Thousands of UK patients with advanced kidney cancer who have been denied a combination regimen based on Ipsen’s Cabometyx and Bristol-Myers Squibb’s Opdivo will now be able to access the treatment, ...
Tired of slow Windows 11 search? Discover six powerful tools that replace it with speed, custom triggers, AI features, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback